RTP Mobile Logo
Lung Cancer Update, Issue 1, 2012
Released June 2012

Featuring interviews with Drs Mark G Kris, Heather Wakelee, Ramaswamy Govindan and David Jablons. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES
    • Apply the results of emerging clinical research to the current and future treatment of non-small cell lung cancer (NSCLC).
    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions and other recently identified driver mutations — and the investigational and approved treatment options for patients with these biomarkers.
    • Describe emerging efficacy and tolerability data with combined EGFR targeting for patients with NSCLC and acquired resistance to EGFR tyrosine kinase inhibitors.
    • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of continuation or switch maintenance biologic therapy and/or chemotherapy.
    • Consider the use of low-dose CT screening in evaluating appropriately selected patients for early-stage lung cancer.
    • Individualize adjuvant chemotherapy for patients with early-stage NSCLC, with consideration of the efficacy and unique side-effect and tolerability profiles of guideline-endorsed regimens.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.
    • Use case-based learning to formulate individualized strategies for the care of patients with lung cancer.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY


    This CME activity contains both audio and print components. The participant should review the CME information and listen to the audio MP3s. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr KrisAdvisory Committee: Pfizer Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Pfizer Inc; Lecture: Roche Laboratories Inc. Dr WakeleePaid Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals. Dr GovindanConsulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc. Dr JablonsConsulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, OSI Oncology; Stock Ownership: Pinpoint Genomics.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology and Lilly USA LLC.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio 

    Last review date: June 2012
    Expiration date: June 2013

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 1, 2012
Released June 2012

Featuring interviews with Drs Mark G Kris, Heather Wakelee, Ramaswamy Govindan and David Jablons. (Text and Audio Content)

Read print: